Summit Therapeutics

Yahoo Finance • yesterday

Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings

We recently published 10 Stocks Exploding Higher: Bitcoin Miners Dominate the List. Summit Therapeutics Inc. (NASDAQ:SMMT) is one of Wednesday's top performers. Summit Therapeutics surged by 16.05 percent on Wednesday to close at $28.27 a... Full story

Yahoo Finance • 2 days ago

Notable Wednesday Option Activity: SMMT, PEP, ZM

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Summit Therapeutics Inc (Symbol: SMMT), where a total of 18,796 contracts have traded so far, representing approximately 1.9 milli... Full story

Yahoo Finance • 2 days ago

Johnson&Johnson, Tesla Lead Market Cap Stock Movers on Wednesday

Wednesday’s market has seen significant movements across various stocks, with mega-cap companies like Johnson & Johnson (NYSE:JNJ) and Tesla Motors (NASDAQ:TSLA) experiencing notable intra-day changes. The trading session has been bustli... Full story

Yahoo Finance • 2 days ago

Johnson&Johnson, Joby Aviation Lead Market Cap Stock Movers on Wednesday

Wednesday’s trading session is showcasing significant movements across various market cap categories, with stocks like Johnson & Johnson (NYSE:JNJ) and Joby Aviation (NYSE:JOBY) experiencing notable intra-day changes. Investors are react... Full story

Yahoo Finance • 9 days ago

Summit Therapeutics (SMMT) Jumps 7.6% on Reports of $15-Billion AstraZeneca Deal

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 10 Stocks Going Wild. Summit Therapeutics jumped by 7.61 percent on Wednesday, a second day, to close at $24.74 apiece as reports about a $15-billion partnership with AstraZeneca contin... Full story

Yahoo Finance • 9 days ago

Summit, AstraZeneca (AZN) in Advanced Talks Over $15 billion Oncology Licensing Deal

AstraZeneca PLC (NASDAQ:AZN) is one of the best high growth stocks. Bloomberg reported on July 3 that AstraZeneca is engaged in negotiations with Summit Therapeutics Inc. (NASDAQ:SMMT) regarding a potential licensing agreement for an exper... Full story

Yahoo Finance • 11 days ago

Tesla, Circle Internet Surge Among Monday's Market Cap Stock Movers

Monday’s trading session is showcasing significant movements across various market cap categories. Mega-cap giants like Tesla Motors (NASDAQ:TSLA) and Palantir Technologies Inc (NASDAQ:PLTR) have experienced notable shifts, while large... Full story

Yahoo Finance • 12 days ago

SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca

Shares of clinical-stage company Summit Therapeutics SMMT rose nearly 9% on Thursday following a report issued by Bloomberg, which stated that pharma giant AstraZeneca AZN is in discussions with the company for a potential licensing deal.... Full story

Yahoo Finance • 13 days ago

Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, Bloomberg News reported that AstraZeneca (NASDAQ:AZN) is in discussions with Summit Therapeutics for a licensing agre... Full story

Yahoo Finance • 15 days ago

Oracle, Datadog Lead Thursday's Market Cap Stock Movers

Thursday’s trading session is presenting a dynamic landscape for investors as stocks across the market cap spectrum experience significant movements. Mega-cap stocks like Servicenow Inc (NYSE:NOW) and Oracle Corp (NYSE:ORCL) are showin... Full story

Yahoo Finance • 15 days ago

Sector Update: Health Care Stocks Mixed Thursday Afternoon

Health care stocks were mixed Thursday afternoon, with the NYSE Health Care Index down 0.1% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 15 days ago

Summit Therapeutics Stock Soars on Report of $15B AstraZeneca Partnership Talks

Avishek Das / SOPA Images / LightRocket via Getty Images Shares of Summit Therapeutics are up more than 35% this year. Shares of Summit Therapeutics (SMMT) jumped 9% Thursday on a report that it was discussing a lucrative partnership deal... Full story

Yahoo Finance • 15 days ago

Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports

(Reuters) -AstraZeneca is in talks with Summit Therapeutics (NASDAQ:SMMT) to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with the matter.... Full story

Yahoo Finance • 15 days ago

Summit said to be in talks with Astra to license potential rival for Merck’s Keytruda

[Prime Minister Scott Morrison Announces Deal With AstraZeneca To Supply Potential COVID-19 Vaccine] Lisa Maree Williams/Getty Images News Summit Therapeutics (NASDAQ:SMMT [https://seekingalpha.com/symbol/SMMT]) shares spiked on Thursday,... Full story

Yahoo Finance • 15 days ago

Summit Therapeutics stock rises after report of potential $15B AstraZeneca deal

Investing.com -- Summit Therapeutics (NASDAQ:SMMT) stock rose 5% on Thursday while AstraZeneca (NASDAQ:AZN) shares fell 2% following a Bloomberg report that the companies are in discussions for a potential $15 billion partnership deal. Ac... Full story

Yahoo Finance • 17 days ago

Summit Therapeutics (SMMT) Rated Buy on Ivonescimab’s Cancer-Fighting Potential

Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. Analysts at H.C. Wainwright reaffirmed their Buy rating on Summit Therapeutics Inc. (NASDAQ:SMMT) on June 2, ci... Full story

Yahoo Finance • 18 days ago

Summit Therapeutics stock initiated with Buy rating at UBS on cancer drug potential

Investing.com - UBS initiated coverage on Summit Therapeutics plc (NASDAQ:SMMT) with a Buy rating and a $30.00 price target, citing the potential of its lead cancer drug candidate. The stock, currently trading at $21.28, has shown remarkab... Full story

Yahoo Finance • 18 days ago

Summit Therapeutics stock initiated with Buy rating at Clear Street

Investing.com - Summit Therapeutics plc (NASDAQ:SMMT) received a Buy rating initiation from Clear Street with a price target of $30.00. According to InvestingPro data, analyst targets for the stock range from $12.19 to $44.80, with the com... Full story

Yahoo Finance • 18 days ago

Revolution Medicines and Summit Therapeutics in-pact for cancer treatments

[Cancer cells vis] koto_feja/E+ via Getty Images * Revolution Medicines (NASDAQ:RVMD [https://seekingalpha.com/symbol/RVMD]) and Summit Therapeutics (NASDAQ:SMMT [https://seekingalpha.com/symbol/SMMT]) announced a clinical partnership t... Full story

Yahoo Finance • 19 days ago

Revolution Medicines, Summit Therapeutics Enter Clinical Collaboration

(RTTNews) - Revolution Medicines, Inc. (RVMD) and Summit Therapeutics, Inc. (SMMT) have entered into a clinical collaboration in multiple solid tumor settings to evaluate the safety and efficacy of each of Revolution Medicines clinical-sta... Full story